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Figure S1. The mammalian N-end rule pathway. N-terminal residues are indicated by 
single-letter abbreviations for amino acids. A yellow oval denotes the rest of a protein substrate. 
E3 ubiquitin (Ub) ligases of the N-end rule pathway are called N-recognins. 
(A) The Arg/N-end rule pathway. “Primary”, “secondary” and “tertiary” denote 
mechanistically distinct subsets of destabilizing N-terminal (Nt) residues. C* denotes oxidized 
N-terminal Cys, either Cys-sulfinate or Cys-sulfonate, produced in vivo by reactions that require 
nitric oxide (NO) and oxygen. Oxidized N-terminal Cys is Nα-terminally arginylated 
(Nt-arginylated) by ATE1-encoded isoforms of arginyl-tRNA-protein transferase (R-transferase), 
which also arginylates N-terminal Asp (D) and Glu (E). N-terminal Asn (N) and Gln (Q) are 
deamidated by the NTAN1-encoded NtN-amidase and the NTAQ1-encoded NtQ-amidase, 
respectively. In addition to their binding sites that recognize primary destabilizing N-terminal 
residues, the UBR1, UBR2, UBR4 and UBR5 (EDD) N-recognins contain binding sites for 
substrates (denoted by a larger oval) with internal (non-N-terminal) degradation signals. 
Polyubiquitylated Arg/N-end rule substrates are processively destroyed to short peptides by the 
26S proteasome. Hemin (Fe3+-heme) binds to R-transferase, inhibits its Nt-arginylation activity 
and accelerates its in vivo degradation. Hemin also binds to UBR-type N-recognins and alters 
them functionally, in ways that remain to be understood. Regulated degradation of specific 
proteins by the Arg/N-end rule pathway mediates the sensing of heme, NO, oxygen, and short 
peptides; the elimination of misfolded proteins; the regulation of DNA repair; the fidelity of 
chromosome cohesion/segregation; the signaling by G proteins; the control of peptide import; the 
regulation of apoptosis, meiosis, viral and bacterial infections, fat metabolism, cell migration, 
actin filaments, cardiovascular development, spermatogenesis, neurogenesis, and memory; and 
the functioning of adult organs, including the brain, muscle, testis and pancreas ((Brower and 
Varshavsky, 2009; Caprio et al., 2010; Choi et al., 2010; Dougan and Truscott, 2011; Eisele and 
Wolf, 2008; Graciet and Wellmer, 2010; Heck et al., 2010; Hu et al., 2008; Hwang et al., 2010a; 
Hwang et al., 2010b; Hwang et al., 2011; Kurosaka et al., 2010; Matta-Camacho et al., 2010; 
Mogk et al., 2007; Nillegoda et al., 2010; Piatkov et al., 2012a; Piatkov et al., 2012b; Tasaki et 
al., 2012; Varshavsky, 2011; Wang et al., 2009; Wang et al., 2011; Zhang et al., 2010), and refs. 
therein).  
(B) The Ac/N-end rule pathway. Although it is virtually certain that this pathway is 
present in all eukaryotes (Varshavsky, 2011), it has been characterized, thus far , only in 
S. cerevisiae (Hwang et al., 2010b). This diagram illustrates the mammalian Ac/N-end rule 
pathway through extrapolation from its S. cerevisiae version. Red arrow on the left indicates the 
removal of N-terminal Met by Met-aminopeptidases (MetAPs). N-terminal Met is retained if a 
residue at position 2 is nonpermissive (too large) for MetAPs. If the retained N-terminal Met or 
N-terminal Ala, Val, Ser, Thr, and Cys are followed by acetylation-permissive residues, the 
above N-terminal residues are Nt-acetylated by ribosome-associated Nt-acetylases (Arnesen et 
al., 2009). The resulting N-degrons are called Ac/N-degrons, to distinguish them from other 
N-degrons (Hwang et al., 2010b; Varshavsky, 2011). Although the second-position Gly or Pro 
residues can be made N-terminal by MetAPs , few proteins with N-terminal Gly or Pro are 
Nt-acetylated (Arnesen et al., 2009). The term “secondary” refers to the Nt-acetylation of a 
destabilizing N-terminal residue before a protein can be recognized by a cognate N-recognin. 
(C) The Ub reference technique (URT), derived from the Ub fusion technique (Piatkov et 
al., 2012a; Suzuki and Varshavsky, 1999; Varshavsky, 2005). Cotranslational cleavage of a 
URT-based fusion by deubiquitylases produces, at the initially equimolar ratio, a test protein 
with a desired N-terminal residue and a “reference” protein such as fDHFR-UbR48, a flag-tagged 
derivative of the mouse dihydrofolate reductase. In URT-based pulse-assays, the labeled test 
protein is quantified by measuring its level relative to the levels of a stable reference at the same 
time point. In addition to being more accurate than pulse-chases without a stable reference, URT 
assays make it possible to detect and measure the degradation of a test protein during the pulse, 
i.e., before the chase (Piatkov et al., 2012a; Varshavsky, 2005). 
Figure S1 refers to Figures 1 and 3. 
 
  
  
 
Figure S2. Evolutionary conservation of the destabilizing nature of P1’ residues in the 
cleavage sites that yield the natural fragments of TDP43, α-Synuclein, and Tau. (A P1’ residue 
becomes N-terminal upon protein cleavage.) 
(A) Domain organization of TDP43. Arrowheads indicate the cleavage sites 1, 2 and 3 in 
full-length TDP43 that yield the natural C-terminal fragments isolated from protein aggregates in 
human FTLD-TDP brains (see Figure 1 and the main text) (Igaz et al., 2009; Nonaka et al., 2009; 
Pesiridis et al., 2011; Wang et al., 2012). The identity of protease(s) that generates these TDP43 
fragments is unknown. The indicated residue numbers, including those of P1’ residues (these 
residues are in color and in a lager font size), are of the full-length human TDP43. Note the 
complete conservation of the P1’ Asp (D) residues at the cleavage sites 2 and 3 (positions 219 
and 247). Note also the “drift-with-constraint” evolutionary pattern of the P1’ residues in the 
cleavage site 1 (see the main text). Specifically, a P1’s residue is Arg (R) in most species but Gln 
(Q), another destabilizing residue, in the mouse, rat, and chicken. 
(B) Domain organization of human α-synuclein. Arrowhead indicates the metalloprotease 
cleavage site (Choi et al., 2011). (Metalloproteases are usually extracellular but can occur in the 
cytosol as well (Cauwe and Opdenakker, 2010).) For notations, see A. Analogously to the 
evolutionary pattern observed with P1’ residues in the cleavage site 1 of TDP43 in A, most P1 
residues in the cleavage site of α-synuclein are Gln (Q), at position 79 of the human α-synuclein. 
However, some mammals (such as guinea pigs), some frogs (such as Xenopus laevis), and some 
fishes (such as pikes) contain His at the P1’ position of their α-synucleins (Figure S2B). Both 
N-terminal Gln and His are destabilizing residues (Figure S1A). Yet another informative aspect 
of evolution of the P1’ residue of α-synuclein is that all changes of the predominant Gln at the 
P1’ position (equivalent to position 79 in human α-synuclein) in separate vertebrate lineages 
(mammals, frogs, fishes) were invariably to His, rather than to another residue. A plausible 
explanation stems from the fact that the CAA/CAG codons for Gln differ from the CAT/CAC 
codons for His by one nucleotide. A similar interpretation is also relevant to the evolutionary 
change of a P1’s residue at position 208 in human TDP43 (panel A): the alteration from Arg to 
Gln at the P1’ position of full-length TDP43 in vertebrates involved a single-base transition 
between the CGG Arg codon and the CAG Gln codon. 
(C) Domain organization of the human Tau-2N isoform. Two arrowheads indicate the 
calpain cleavage sites. In the first of them, the P1’ residue of human Tau is Glu (E), at position 3. 
The third cleavage site is specific for caspases, in particular caspase-6, with the P1’ residue being 
His (H), at position 14 (Spires-Jones et al., 2011; Zilka et al., 2012). In yet another example of 
the drift-with-constraint evolutionary pattern of P1’ residues seen above with TDP43 and α-
synuclein (panels A and B), the P1’ residue at position 3 of the calpain cleavage site of Tau-2N 
is Glu in humans, horses, rats, chickens and other vertebrates, but is Asp in mice. Both His, Glu 
and Asp are destabilizing residues (Figure S1A). Caspases have been shown to cleave human 
Tau-2N between Asp13 and His14, and also 19 residues upstream of its C-terminus, at Asp421-
Ser422, with the former cleavage mediated by at least caspase-6 ((Horowitz et al., 2004) and 
refs. therein). The Asp13-His14 cleavage produces the N-terminally truncated Tau bearing 
N-terminal His, a destabilizing residue. The resulting His14-Tau is yet another (predicted) 
physiological substrate of the Arg/N-end rule pathway. All but one among the examined 
mammalian Tau sequences has His at the P1’ position (this residue becomes N-terminal after 
caspase cleavage). The only exception, rat Tau, has Gln (Q) at this position, but both His and Gln 
are destabilizing residues, a recurrent example of the drift-with-constraint pattern of P1’ residues 
described above for other neurodegeneration-associated fragments. 
The evolutionary retention of a destabilizing nature of a P1’ residue in a precursor of a 
caspase-generated fragment of any protein (not only of Tau) is noteworthy for an additional and 
independent reason as well. More than 90% of caspase cleavage sites in cellular proteins contain, 
at their P1’ positions, small residues such as Gly, Ser , Thr and Ala (Crawford and Wells, 2011; 
Pop and Salvesen, 2009). These residues are not recognized by the Arg/N-end rule pathway 
(Figure S1A). Thus, remarkably, the destabilizing P1’ residues His or Gln in the precursors of 
caspase-generated X14-Tau fragments in different mammals (let alone the evolutionary 
conservation of these residues) would not be expected on a priori grounds, given the major 
preponderance of smaller P1’ residues in caspase substrates at large. Together with our previous 
findings (Piatkov et al., 2012a; Varshavsky, 2012), these results strongly suggest adaptive 
(fitness-increasing) origins of the observed destabilizing P1’ residues in the precursors of the 
TDP43, α-synuclein, and Tau fragments examined in the present work. 
Figure S2 refers to Figures 1, 2 and 3. 
 
 
 
 
Figure S3. The Natural C-Terminal Fragment of Human Tau-1N As a Short-Lived 
Substrate of the Arg/N-End Rule Pathway. 
(A) Domain organization of human Tau-1N. Arrowheads indicate the calpain cleavage 
sites. See also Figure 3D-F and the main text. 
(B) The N-terminus-proximal cleavage site is indicated by an arrowhead, with the P1’ 
Glu (E) residue shown in red. The X3-Tau-1N95 fragments, produced from 
fDHFR-UbR48-X3-Tau-1N95 fusions (X= Glu, Val) in reticulocyte extract, were assayed for 
degradation as described in the legend to Figure 1B. 
(C) Quantification of B using the reference protein fDHFR-UbR48. 
Figure S3 refers to Figure 3D, E. 
 
  
  
 
Figure S4. 35S-Pulse-Chase Assays in S. cerevisiae with URT fusions encoding 
X-Aβ4213myc. 
(A) The fDHFR-UbR48-Asp-Aβ4213myc URT-type fusion, was expressed in wt, ate1Δ, or 
ubr1Δ S. cerevisiae as described in Supplemental Experimental Procedures. The fusion’s 
cotranslational cleavage by deubiquitylases produced the reference fDHFR-UbR48 and the test 
protein Asp-Aβ4213myc. These proteins were pulse-labeled with 35S-Met/Cys for 5 min at 30°C, 
followed by the chase for 0, 10 and 20 min, preparation of cell extracts, immunoprecipitation 
with anti-myc/anti-flag antibodies, SDS-PAGE and autoradiography. Lane 1, S. cerevisiae were 
transformed with vector alone (negative control). Lanes 2-4, Asp-Aβ4213myc and fDHFR-UbR48 in 
ate1Δ cells lacking Nt-arginylation. Lanes 5-7, same as lanes 2-4 but in wt S. cerevisiae. Lanes 
8-10, the same as lanes 2-4 but in ubr1Δ cells lacking the N-recognin of the Arg/N-end rule 
pathway. The bands of 35S-labeled Asp-Aβ4213myc and fDHFR-UbR48 are indicated on the left. 
(B) Quantification of A. 
(C) Same as in A but fDHFR-UbR48-Met-Aβ4213myc whose in vivo cleavage by 
deubiquitylases yields Met-Aβ4213myc.  
(B) Quantification of C. 
Figure S4 refers to Figures 4 and 5. 
  
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Miscellaneous Reagents 
Cycloheximide was from Sigma (St. Louis, MO). Human cDNAs encoding proteins 
examined in the present work were from OpenBiosystems (Huntsville, AL). MG132 (BML-
PI102-0005) and clasto-Lactacystin β-Lactone (BML-PI108-0100) were from EnzoLife Sciences 
(Farmingdale, NY). Epoxomicin (E3652), Thiorphan (T6031), Racecadotil (SML0043), 
Phosphoramidon (R7385) and Verapamil (V4629) were from Sigma. The following antibodies 
were used: anti-FLAG M2 (Sigma, F1804), anti-c-Myc (Sigma, C3956), anti-Beta-Amyloid 
(4G8) (Covance, SIG-39220), anti-Amyloid Precursor Protein (Calbiochem, 171610); and 
affinity-purified polyclonal antibody to mouse Ate1 (Hu et al., 2005). The following reagents 
were used for immunoprecipitation: anti-flag M2 Magnetic Beads (Sigma, M8823) and EZview 
Red anti-c-Myc affinity gel (Sigma, E6654). Detection was carried out using HRP-conjugated 
goat anti-Rabbit (BioRad, 170-6515) or anti-mouse (BioRad, 170-6516) antibodies and either 
ECL Prime Western Blotting Detection System (GE Healthcare, UK) or SuperSignal West 
Femto reagents (Thermo Scientific, Rockford, IL), according to manufacturers’ protocols. 
5xFAD mice were obtained from The Jackson Laboratories (JAX stock number 006554). 
Postmortem human brain tissue was obtained from the Harvard Brain Tissue Resource Center. 
 
Plasmids, cDNAs, and Primers 
DH5α E. coli (Invitrogen) was used for cloning and maintaining plasmids. Phusion 
High-Fidelity DNA polymerase (New England Biolabs) was used for polymerase chain reaction 
(PCR). Sequences of all constructed plasmids were verified by DNA sequencing. 
Asp-Aβ4213myc. cDNA encoding human Aβ42 sequence (Figure 4A) was amplified by 
PCR using a set of overlapping forward primers (CB302F, CB268F, CB269F, CB270F, and 
CB271F) and reverse primers (CB272R, CB273R, CB274R, and CB304R) (Table S2) whose 
assembled sequence contained DNA encoding human Aβ42. The resulting DNA fragment was 
inserted into pFA6a-13Myc-kanMX6 (Table S1) using SacII/SmaI sites to produce pCB253. The 
Aβ4213myc-coding sequence was removed from pCB253 using SacII/EcoRI and inserted into 
SacII/EcoRI-cut pCH280 (Hwang et al., 2009) to produce pCB255, a low copy plasmid which 
was used to express fDHFR-UbR48-Asp-Aβ4213myc from the PMET25  promoter in S. cerevisiae. 
fDHFR-UbR48-X-Aβ4213myc fusions (X=Met, Val, Arg-Asp) were constructed by amplifying the 
human Aβ42-coding DNA fragment with the following sets of primers: CB313F and CB304R 
(Met-Aβ4213myc); CB314F and CB304R (Val-Aβ4213myc); CB316F and CB304R 
(Arg-Asp-Aβ4213myc). The resulting fragments were cut with SacII and SmaI, and cloned into 
SacII/SmaI-cut pCB255 to produce the plasmids pCB255, pCB282, pCB284, and pCB285 
(Table S1). For 35S-pulse-chase URT-based assays in rabbit reticulocyte extract, the DNA 
fragment encoding fDHFR-Ub-Asp-Aβ13myc was removed from pCB255 by HindIII digestion and 
inserted into HindIII-cut pcDNA3.0 (Invitrogen) to produce pCB268 (Table S1).  
TDP43. The human Tdp43 cDNA was obtained from OpenBiosystems 
(ID: LIFESEQ2505218). DNA fragments encoding X208-TDP43 C-terminal fragments (X=Arg, 
Met, Gln, and Glu) were constructed by amplification, using the following sets of primers: 
CB320F and CB327R (Arg208-TDP43); CB321F and CB327R (Met208-TDP43); CB322F and 
CB327R (Gln208-TDP43); and CB323F and CB327R (Glu208-TDP43) (Table S2).  C-terminal 
flag tags were added by sequential PCR extension using the above forward primers with, at first, 
CB275R, and then CB280R. The resulting PCR products, which encoded X208-TDP43f, were 
cut with SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB322, 
pCB323, pCB234, and pCB325 (Table S1). DNA encoding X219-TDP43f C-terminal fragments 
(X=Asp, Met, Val, and Arg-Asp) were amplified from pCB323 using the following sets of 
primers: CB330F and CB329R (Asp219-TDP43f); CB331F and CB329R (Met219-TDP43f); 
CB332F and CB329R (Val219-TDP43f); and CB333F and CB329R (ArgAsp219-TDP43f). DNA 
encoding X247-TDP43f C-terminal fragments (X=Asp, Met, Val, and Arg-Asp) were amplified 
from pCB323 using the following sets of primers: CB334F and CB329R (Asp247-TDP43f); 
CB335F and CB329R (Met247-TDP43f); CB336F and CB329R (Val247-TDP43f); and CB337F 
and CB329R (Arg-Asp247-TDP43f). The resulting PCR products, which encoded either 
X219-TDP43f or X247-TDP43f, were cut with SacII/XbaI and cloned into SacII/XbaI-cut 
pCB268, producing the plasmids pCB326-pCB333 (Table S1). 
For mammalian expression using the weaker (relative to the PCMV promoter) PSV40 
promoter, DNA fragments encoding the fDHFR-Ub-X-TDP43f fusions in pcDNA3.0-based 
plasmids (containing the PCMV promoter) were used to replace the luciferase reporter in 
pGL3-Control plasmid (Promega) after digestion with HindIII/XbaI. 
To construct the plasmid pCB400, used in in vivo aggregation assays (Figure 2C-E), 
DNA encoding mCherry was amplified from pKP551 (Table S1) using primers CB383F and 
CB384R, and the resulting PCR product was used to replace the fDHFR moiety in pCB338 after 
digestion with HindIII/AgeI . 
α-Synuclein. The human α-synuclein cDNA was obtained from OpenBiosystems 
(ID: 5287266). DNA encoding X79- αSynf (X= Gln and Val) were constructed by amplification 
with the following sets of primers: CB364F and CB367R (Gln79-αSyn); and CB365F and 
CB367R (Val79-αSyn). The resulting DNA fragments were cut with SacII/XbaI, and cloned into 
SacII/XbaI-cut pCB268, generating the plasmids pCB347 and pCB348 (Table S1). 
Tau. The human Tau-1N cDNA (lacking exon 3) was obtained from OpenBiosystems 
(ID: LIFESEQ6770882). DNA encoding X3-Tau-1N95f (X= Glu and Val) were constructed by 
amplification with the following sets of primers: CB373F and CB377R (Glu3-TauN1) and 
CB375F and CB377R (Val3-TauN1). CB377 encoded the C-terminal sequence 
PGSDYKDDDDK, containing the linker and the flag epitope. Human Tau-2N cDNA 
(containing exon 3) was obtained by a three-step PCR strategy whereby the N-terminal portion 
of the Tau3-124-coding fragment was amplified using the above forward primers and CB379R 
(whose 5’-proximal region is the reverse complement of the 5’-region of CB380F). The C-
terminal portion of the Tau3-124-coding fragment was amplified using CB380F (whose 5’-
proximal region is the reverse complement of the 5’-region of CB379R) and CB377R. The entire 
Tau-2N3-124-coding fragment was amplified using the overlapping N- and C-terminal fragments 
as templates in a final PCR step that employed CB373F and CB377R (Glu3-Tau-2N124) as well 
as CB375F and CB377R (Val3-Tau-2N124). The resulting DNA fragments were cut with 
SacII/XbaI and cloned into SacII/XbaI-cut pCB268, producing the plasmids pCB383, pCB385, 
pCB386, and pCB388 (Table S1). 
 
In Vitro Transcription-Translation-Degradation Assay 
The TNT T7 Coupled Transcription/Translation System, a version of the Promega’s 
rabbit reticulocyte extract preparation in which the main components of the system were 
supplied separately, was used to carry out transcription-translation-degradation assays. Reaction 
samples were prepared according to the manufacturer’s instructions. Nascent proteins in 
reticulocyte extract were pulse-labeled with [35S]L-methionine (0.55 mCi/ml, 1,000 Ci/mmol, 
MP Biomedicals) for 10 min at 30°C, in the total volume of 30 µl. The labeling was quenched by 
the addition of cycloheximide and unlabeled methionine, to the final concentrations of 0.1 mg/ml 
and 5 mM, respectively. Samples were withdrawn at indicated timepoints of a chase and the 
reactions were terminated by the addition of 0.1 ml of TSD buffer (1% SDS, 5 mM dithiothreitol 
(DTT), 50 mM Tris-HCl, pH 7.4) and snap-freezing in liquid nitrogen. Samples were then heated 
at 95°C for 10 min, diluted with 10 volumes of TNN buffer (0.5 % NP-40, 0.25 M NaCl, 5 mM 
EDTA, 50 mM Tris-HCl, pH 7.4), containing the “complete protease-inhibitor mixture” (Roche), 
clarified by centrifugation at 20,000g for 5 min and immunoprecipitated using 5 μl of beads with 
an immobilized antibody, either anti-flag M2 Magnetic Beads or EZview Red anti-c-Myc 
affinity gel. The immunoprecipitates were incubated with rocking at 4°C for 3 hr, followed by 
3 washes in TNN buffer, one wash in 10 mM Tris-HCl (pH 8.5), and resuspension in 20 μl of 
SDS-sample buffer.  Samples were then heated at 95°C for 10 min and fractionated by SDS-4-
15% PAGE, followed by autoradiography, using Storm PhosphorImager (Molecular Dynamics, 
Sunnyvale, CA), and quantification, using ImageQuant (GE Healthcare). 
 
Cell Culture 
Mouse NIH-3T3 and human HEK-293T cells were obtained from American Type 
Culture Collection (ATCC, Manassas, VA). Ate1-/- mouse embryonic fibroblasts (EFs) were 
described previously (Kwon et al., 2002). Cells were grown at 37°C in 5% CO2 in DMEM 
medium supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-Products, West 
Sacramento, CA) and penicillin/streptomycin (100 units/ml) (Hyclone).  Cells were transfected 
using Lipofectamine-2000 (Invitrogen) according to the manufacturer’s protocol.  
 
In Vivo Degradation Assay 
Human embryonic kidney-293T cells (~75% confluent) were transfected with 1 µg 
plasmid per 35-mm well using Lipofectamine-2000 according to the manufacturer’s protocol.  
Forty hours post-transfection cells were pulse-labeled for 15 min with [35S]L-methionine 
(0.1 mCi/ml, MP Biomedicals) in DMEM lacking Met and Cys. Labeling was quenched by the 
addition of cycloheximide (0.1 mg/ml) in complete DMEM (containing Met as well). Cells 
contained in an entire 35-mm well were lysed at the indicated timepoints of a chase by rapid 
scraping in 150 µl of TSD buffer (see above) and snap freezing in liquid nitrogen. Samples were 
then heated at 95°C for 10 min and diluted with 10 volumes of TNN buffer (see above) 
containing the “complete protease-inhibitor mixture” (Roche). Total 35S (in the 10% 
CCl3COOH-insoluble fraction) in samples was then measured, and volumes were adjusted to 
equalize 35S among different samples. Thus prepared samples were immunoprecipitated by the 
addition of 5 μl of anti-flag M2 magnetic beads and incubation with rocking at 4°C for 3 hr. 
Immunoprecipitated proteins were then washed 3 times in TNN buffer and once in 10 mM Tris-
HCl (pH 8.5), followed by resuspension in 20 μl of SDS-sample buffer, heating at 95°C for 10 
min, SDS-4-15% PAGE, and autoradiography, with quantification as described above. 
 
In Vivo Aggregation Assay 
Poly-D-lysine (1 mg/ml)-coated coverslips were placed in 35-mm tissue culture dishes 
and 1.5 × 105 mouse embryonic fibroblasts (NIH-3T3 or Ate1-/-) were seeded on top and grown 
until ~65% confluency. Cells were then transfected with 1 µg of pCB400 per plate, using 
Lipofectamine-2000. Twenty-four hrs after transfection, cells were fixed in 4% formaldehyde for 
10 min at room temperature, and permeabilized in 0.5% Triton-X100 in PBS for 10 min at room 
temperature. Coverslips were then washed three times in PBS, and blocked in 10% goat serum 
for 30 min. Coverslips were incubated with anti-flag M2 antibody (at 1/1000 dilution in 5% goat 
serum/PBS containing 0.1% Tween-20) for 2 hrs at 37°C in a humid environment, followed by 
three 5 min washes in PBS containing 0.1% Tween-20 and incubation with 
fluorescein-conjugated anti-mouse secondary antibody (Pierce, #31567) (at 1/200 dilution in 5% 
goat serum/PBS containing 0.1% Tween-20) for 1 hr at 37°C in a humid environment. 
Coverslips were again washed 3 times in PBS containing 0.1% Tween-20, and thereafter were 
mounted using Vectashield H-1500 mounting medium containing DAPI (Vector Laboratories, 
Burlingame, CA). Thus processed coverslips were examined for fluorescence by mCherry, 
DAPI, and fluorescein-conjugated secondary anti-mouse antibody using Zeiss Axio Imager 2. 
 
Steady-State and Pulse-Chase Assays of X-Aβ4213myc in S. cerevisiae 
S. cerevisiae JD52 (MATa, trp1-Δ63, ura3–52, his3-Δ200, leu2–3112, lys2-801) and 
JD55 (ubr1Δ::HIS3 in JD52) were described previously(Ghislain et al., 1996). S. cerevisiae 
CHY21 (ate1Δ::KanMX6 in JD52) and CHY22 (ubr1Δ::HIS3 in CHY21) were gifts from 
Dr. Cheol-Sang Hwang. S. cerevisiae media included YPD (1% yeast extract, 2% peptone, 2% 
glucose; only most relevant media components are cited); SD medium (0.17% yeast nitrogen 
base, 0.5% ammonium sulfate, 2% glucose); and synthetic complete (SC) medium (0.17% yeast 
nitrogen base, 0.5% ammonium sulfate, 2% glucose, plus a drop-out mixture of compounds 
required by auxotrophic strains). S. cerevisiae were transformed with the low copy pCB255, 
pCB282, pCB284, or pCB285 plasmids using standard techniques (Ausubel et al., 2010). 
Expression of fDHFR-Ub-X-Aβ13myc was induced by growth in SD(-Ura, -Met) for 6 hr at 30°C. 
35S-pulse-chase experiments with S. cerevisiae were performed essentially as described 
previously (Hwang et al., 2009). Transformed yeast strains carrying low copy plasmids 
expressing test protein fusions were grown in 10 ml of SD(-Ura) medium at 30°C until A600 
of ~1.0. Cells were pelleted by centrifugation at 3,000g for 10 min and washed with 0.8 ml of 
fresh pre-warmed medium. Cell pellets were gently resuspended in 0.4 ml of the same medium 
but lacking Met/Cys, and incubated for 10 min at 30°C, followed by labeling for 5 min with 
[35S]L-methionine (0.55 mCi/ml, 1,000 Ci/mmol; MP Biomedicals). Cells were then pelleted by 
centrifugation and resuspended in 0.4 ml of YPD medium containing cycloheximide at 0.1 
mg/ml (chase medium). Samples (0.1 ml) were taken at the indicated time points and added to 
0.8 ml of the lysis buffer (1% TritonX-100, 0.15 M NaCl, 5 mM EDTA, 1 mM PMSF 
(phenylmethylsulfonyl fluoride, freshly dissolved), 50 mM HEPES, pH 7.5) containing “yeast 
protease inhibitor cocktail” (Roche), followed by rapid freezing in liquid nitrogen. Samples were 
thawed in thermomixer (Eppendorf) at 37°C for 2 min and thereafter treated by 4 runs in lysing 
matrix C (0.1 mM silica spheres) using FastPrep-24 (MP Biomedicals) (setting 6.5 m/s, 20 sec, 
with 2 min on ice between the runs). The resulting samples were centrifuged at 20,000g, and 
total 35S (in the 10% CCl3COOH-insoluble fraction) in each sample was adjusted, by dilution 
with lysis buffer, to equalize 35S among different samples. Thus prepared samples were 
immunoprecipitated using EZview Red anti-cMyc affinity gel. The unbound material was 
immunoprecipitated using anti-flag M2 magnetic beads. Immunoprecipitated proteins were 
fractionated by SDS-4-15% PAGE, electrophoretically transferred to PVDF membranes, 
detected by autoradiography, and quantified, using Storm PhosphorImager and ImageQuant. 
 
Animal Care and Treatments 
All animal care and procedures were carried out according to the NIH guidelines, and 
were approved by the Institutional Animal Care and Use Committee and the Office of 
Laboratory Animal Research (OLAR) at the California Institute of Technology. Mice were 
housed at ~22°C using a 12 hr light/12 hr dark cycle, with Laboratory Rodent Diet 5001 (PMI 
International, Richmond, IN) ad libitum. The proteasome inhibitors MG132 (25 µmol/kg) clasto-
lactacystin β-lactone (1 µmol/kg), and epoxomicin (0.6 µmol/kg), as well as neprilysin inhibitors 
Thiorphan (12 mg/kg), Racecadotil (18 mg/kg), and Phosphoramidon (2.5 mg/kg), in addition to 
verapamil (45 mg/kg), an inhibitor of multidrug resistance transporters, were delivered 
intraperitoneally (two injections, 12 hrs apart). Twelve hours after the last injection, mouse 
brains were harvested and proteins were extracted as described below. 
 
Tissue Extracts and Immunoblotting 
Proteins were extracted from mouse and human brain samples using a three-step 
sequential procedure. First, brain tissue (225 mg per ml of buffer) was homogenized in TBS 
buffer (0.15 M NaCl, 50 mM Tris-HCl, pH7.4) containing “complete protease-inhibitor mixture” 
(Roche), using FastPrep-24 and Lysing Matrix D (MP Biomedicals), with 3 runs at 6.5 m/s for 
30 sec each, and with 5-min incubations on ice between runs. TBS-insoluble material was 
pelleted by centrifugation at 100,000g for 40 min at 4°C in the TL-100.3 ultracentrifuge. The 
pellets were washed in TBS, and resuspended in TBS-X (TBS containing 1% Triton-X100) by 
rotation at 4°C for 30 min TBS-X-insoluble material was precipitated by centrifugation at 
100,000g for 40 min at 4°C, washed in TBS, and resuspended in 70% HCOOH (formic acid 
(FA)), using multiple passages through a 26 gauge needle and overnight rotation 4°C. Material 
insoluble in 70% HCOOH was pelleted by centrifugation at 22,000g for 10 min at 4°C. Protein 
concentrations in TBS, TBS-X, and FA extracts were determined using Bio-Rad Protein Assay 
DyeReagent (BioRad, # 500-0006). HCOOH extracts were additionally dried in a Speed-Vac and 
washed with acetone. Equal total protein amounts from each sample were fractionated by 
SDS-16.5% PAGE (Criterion Tris-Tricine gels; BioRad, #345-0063), and proteins were 
transferred to 0.2 µm nitrocellulose membranes (BioRad, # 162-0112), which were then 
autoclaved in H2O to enhance epitope exposure to antibodies (Swerdlow et al., 1986), followed 
by immunoblotting with the specified antibodies. Detection was carried out using ECL Prime 
Western blotting Detection System (GE Healthcare, UK) or SuperSignal West Fempto reagents 
(Thermo Scientific, Rockford, IL) according to manufacturer’s protocol. 
 
In Vitro Arginylation Assay 
In vitro Ate1 arginyl-transferase (R-transferase) assays were carried out in 50-μl samples largely 
as described previously (Hu et al., 2006). The samples contained either zero, 0.1, or 1.0 µg of 
purified recombinant Ate1-1, Ate1-2, Ate1-3, or Ate1-4 mouse transferase (Hu et al., 2006) (Hu 
et al., 2005) and 0.5 mg/ml of chemically synthesized Aβ42 (Sigma, A9810), total E. coli tRNA 
(0.6 mg/ml) (Sigma), total E. coli aminoacyl-tRNA synthetases (800 U/ml) (Sigma), 1 mM ATP, 
30 mM KCl, 2 mM MgCl2, 2 mM β-mercaptoethanol, 2 μM L-arginine, 10 mM Tris-HCl (pH 
8.0) and 0.1 μM [14C]L-arginine (PerkinElmer, NEN Radiochemicals, Waltham, MA). A 
reaction mixture (50 μl) was incubated for 30 min at 37°C, followed by the addition of the equal 
volume of 2xSDS sample buffer. Samples were then heated at 95°C for 10 min, followed by 
SDS-16.5% PAGE (Criterion Tris-Tricine gels; BioRad, #345-0063), electrophoretic transfer to 
0.2 μm PVDF membranes using the iBlot apparatus (Invitrogen), and both autoradiography and 
immunoblotting, as described in the legend to Figure 4D. 
 
Antibody Specific for Arg-Asp-Aβ 
Rabbit peptide-mediated antibody to RDAEFRHDSGYC, the Nt-arginylated N-terminal 
sequence of Aβ42 (except for C-terminal Cys, which was used to conjugate the peptide to 
keyhole limpet hemocyanin, a carrier protein) was produced by Abgent (San Diego, CA), using 
standard methods. The peptides RDAEFRHDSGYC and its “non-arginylated” counterpart 
DAEFRHDSGYC were synthesized and purified also by Abgent. The resulting antibody (its IgG 
fraction, produced using immobilized Protein A) was affinity-purified, “positively” at first, 
against the immobilized RDAEFRHDSGYC peptide. The peptide-bound antibody was eluted 
and thereafter “negatively” purified against the DAEFRHDSGYC peptide (immobilized using 
SulfoLink Coupling Resin (Pierce)), with collection, this time, of the unbound antibody fraction. 
The resulting antibody was characterized as described in Figure 5A and the main text, and was 
then used to detect Nt-arginylated Arg-Asp-Aβ42. Immunoblotting was carried out (with the 
antibody at 1 μg/ml) overnight at 4°C in 5% skim milk in TBS-T (TBS containing 0.1% Tween-
20). Goat anti-rabbit secondary antibody conjugated to horseradish peroxidase was used at 
1:2,000 dilution, and detection was performed using one of the two above-described 
chemilumenescence systems. 
 
  
Table S1. Plasmids used in this study. 
Plasmid Description Source or Reference 
pcDNA3.0-Neo Amp
R; NeoR; Expression vector for cloning 
your gene of interest 
Invitrogen 
pGL3-Control Amp
R; luciferase reporter driven by SV40 
promoter. Also contains the SV40 enhancer. 
Promega 
pAF6a-13myc-
kanMX6 
AmpR; KanR; Yeast genomic targeting Addgene 
pCH280 AmpR; pRS416MET25-fDHFR-UbK48R-
MGT1f 
(Hwang et al., 2009) 
pKP551 AmpR; Trp, pBAM- UbK48R-V-eK-
mCherry-Flag-Myc. 
This study 
IMAGE clone: 
5287266 
AmpR; 3’ full length human α-synuclein 
cDNA 
Open Biosystems 
Clone: 
LIFESEQ2505218 
AmpR; full length human TDP43 cDNA Open Biosystems 
Clone: 
LIFESEQ6770882   
AmpR; 5’ portion of human Tau-1N cDNA 
(lacking exon 3) 
Open Biosystems 
pCB253 AmpR; KanR; pAF6a-13myc-kanMX6 
containing Aβ42-13myc tag 
This study 
pCB255 AmpR; pRS416MET25-fDHFR-UbK48R-
Aβ42 13myc 
This study 
pCB268 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Aβ42 13myc under 
the control of T7 or CMV promoter 
This study 
pCB282 AmpR; pRS416MET25-fDHFR-UbK48R- 
Val-Aβ42 13myc 
This study 
pCB284 AmpR; pRS416MET25-fDHFR-UbK48R- 
Arg-Asp-Aβ42 13myc 
This study 
pCB285 AmpR; pRS416MET25-fDHFR-UbK48R- 
Met-Aβ42 13myc 
This study 
pCB322 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Arg208-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB323 AmpR; NeoR; pcDNA3.0-based plasmid This study 
encoding fDHFR-UbK48R-Met208-TDP43f 
under the control of T7 or CMV promoter   
pCB324 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Gln208-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB325 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R- Glu208-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB326 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Asp219-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB327 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Met219-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB328 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Val219-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB329 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-ArgAsp219-
TDP43f under the control of T7 or CMV 
promoter 
This study 
pCB330 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Asp247-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB331 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Met247-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB332 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Val247-TDP43f 
under the control of T7 or CMV promoter 
This study 
pCB333 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-ArgAsp247-
TDP43f under the control of T7 or CMV 
promoter 
This study 
pCB334 AmpR; pGL3-Control-based plasmid 
encoding fDHFR-UbK48R-Asp219-TDP43f 
under the control of SV40 promoter 
This study 
pCB336 AmpR; pGL3-Control-based plasmid 
encoding fDHFR-UbK48R-Val219-TDP43f 
under the control of SV40 promoter 
This study 
pCB338 AmpR; pGL3-Control-based plasmid 
encoding fDHFR-UbK48R-Asp247-TDP43f 
under the control of SV40 promoter 
This study 
pCB340 AmpR; pGL3-Control-based plasmid 
encoding fDHFR-UbK48R-Val247-TDP43f 
under the control of SV40 promoter 
This study 
pCB341 AmpR; pGL3-Control-based plasmid 
encoding fDHFR-UbK48R-ArgAsp247-
TDP43f under the control of SV40 
promoter. 
This study 
pCB347 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Gln79-αSynf 
under the control of T7 or CMV promoter 
This study 
pCB348 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Val79-αSynf 
under the control of T7 or CMV promoter 
This study 
pCB383 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Glu3-Tau-2N3-124f 
under the control of T7 or CMV promoter 
This study 
pCB385 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Val3-Tau-2N3-124f 
under the control of T7 or CMV promoter 
This study 
pCB386 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Glu3-Tau-1N95f 
under the control of T7 or CMV promoter 
This study 
pCB388 AmpR; NeoR; pcDNA3.0-based plasmid 
encoding fDHFR-UbK48R-Val3-Tau-1N95f 
under the control of T7 or CMV promoter 
This study 
pCB400 AmpR; pGL3-Control-based plasmid 
encoding mCherry-UbK48R-Asp247-TDP43f 
under the control of SV40 promoter 
This study 
  
Table S2. PCR Primers used in this study 
Primer Primer’s sequence (5’ to 3’) 
CB268 ATATGAGGTTCATCATCAAAAATTGGTGTTCTTTGCTGAA 
CB269 GATGTGGGTTCAAACAAAGGTGCGATCATTGGACTCATGG 
CB270 TGGGCGGTGTTGTCATAGCGTCTGGTTCCGACTACAAGGA 
CB271 CGATGATGACAAGTAAGAATTCGATC 
CB272 TTTGATGATGAACCTCATATCCAGAATCATGTCGGAACTC 
CB273 CCTTTGTTTGAACCCACATCTTCAGCAAAGAACACCAATT 
CB274 CGCTATGACAACACCGCCCACCATGAGTCCAATGATCGCA 
CB275 GATCGAATTCTTACTTGTCATCATCGTCCTTGTAGTCGGAACCA
GA 
CB280 GATCGGGCCCTCTAGATCACTTGTCATCGTCGTCCTTG 
CB302 GATCGGATCCCCGCGG TGGTGATGCGGAG 
CB304 GATCCCCGGGCGCTATGACAACACCGCCCACC 
CB313 GATCCGCGGTGGTATGGCAGAGTTCCGACATGATTCTGGATATG 
CB314 GATCCGCGGTGGTGTAGCAGAGTTCCGACATGATTCTGGATATG 
CB316 GTTCCGCGGTGGTAGGGATGCAGAGTTCCGACATGATTCTGGAT
ATG 
CB320 GAATCCGCGGTGGTAGGGAGTTCTTCTCTCAGTACGGGG 
CB321 GAATCCGCGGTGGTATGGAGTTCTTCTCTCAGTACGGGG 
CB322 GAATCCGCGGTGGTCAGGAGTTCTTCTCTCAGTACGGGG 
CB323 GAATCCGCGGTGGTGAAGAATTCTTCTCTCAGTACGGGG 
CB327 GTCCTTGTAGTCGGATCCAGACATTCCCCAGCCAGAAGACTT 
CB329 AATAGGGCCCTCTAGATCACTTGTCATCGTC 
CB330 GAATCCGCGGTGGTGATGTCTTCATCCCCAAGCCATTCAGGGCC 
CB331 GAATCCGCGGTGGTATGGTCTTCATCCCCAAGCCATTCAGGGCC 
CB332 GAATCCGCGGTGGTGTGGTCTTCATCCCCAAGCCATTCAGGGCC 
CB333 GAATCCGCGGTGGTAGAGATGTCTTCATCCCCAAGCCATTCAGG
GCC 
CB334 GAATCCGCGGTGGTGACTTGATCATTAAAGGAATCAGCGTTC 
CB335 GAATCCGCGGTGGTATGTTGATCATTAAAGGAATCAGCGTTC 
CB336 GAATCCGCGGTGGTGTGTTGATCATTAAAGGAATCAGCGTTC 
CB337 GAATCCGCGGTGGTAGAGACTTGATCATTAAAGGAATCAGCGT
TC 
CB364 GAATCCGCGGTGGTCAGAAGACAGTGGAGGGAGCAGGG 
CB365 GAATCCGCGGTGGTGTGAAGACAGTGGAGGGAGCAGGG 
CB367 GAATCCCGGGGGCTTCAGGTTCGTAGTCTTG 
CB373 GAATCCGCGGTGGTGAGCCAAGACAGGAGTTCGAAGTGATGGA
AG 
CB375 GAATCCGCGGTGGTGTGCCAAGACAGGAGTTCGAAGTGATGGA
AG 
CB377 GATCTCTAGATTACTTGTCATCGTCATCCTTGTAGTCAGACCCG
GGTTGGGTCACGTGACCAGCAGC 
CB379 GGGGCTGCGCGGCAGCCTGCTTGCCGGGAGCTCCCTCATCCACT
AAGGGTGCTGTCACATCTTCCGCTGTTGGAGTGCTC 
CB380 GCTCCCGGCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCC
CAGAAGGAACCACAGCTGAAGAAGCAGGCATTGGAG 
CB383 GATCAAGCTTCCCACCATGGTGAGCAAGGGCGAGGAGG 
CB384 
 
GATCACCGGTCAGAGTCTTGACGAAAATCTGCATGGTCGACCCA
CTCTTGTACAGCTCGTCCATGCC 
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